Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening
Ling Li(Tumor Hospital of Guangxi Medical University), Jianjun Chen(Southern Medical University), Bulian Deng(Southern Medical University), Ruiyao Mai(Southern Medical University), Jin Liu(Southern Medical University), Zichao Yang(Southern Medical University), Junli Huang(Academy of Medical Sciences), Huiting Zhao(Jiangsu University), Yichang Ren(Southern Medical University)
Cited by 29
Related Papers
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
|The Lancet|2021|234
Novel CRBN-Recruiting Proteolysis-Targeting Chimeras as Degraders of Stimulator of Interferon Genes with In Vivo Anti-Inflammatory Efficacy
|Journal of Medicinal Chemistry|2022|94
Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity
|Bioorganic Chemistry|2021|40
Biosynthetic molecular imaging probe for tumor-targeted dual-modal fluorescence/magnetic resonance imaging
|Biomaterials|2020|39
<p>The Effect of Size, Dose, and Administration Route on Zein Nanoparticle Immunogenicity in BALB/c Mice</p>
|International Journal of Nanomedicine|2019|31